You just read:

Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019

News provided by

Blueprint Medicines

Jun 03, 2019, 09:00 ET